Two suppliers can quote the same 30-billion-CFU probiotic capsule and still be offering two different products.
One price may be calculated from the amount of probiotic culture added during blending. The other may include additional culture, finished-product CFU testing and packaging selected around an end-of-shelf-life potency target.
Until those details are aligned, the price per bottle is only a partial number.
When comparing probiotic supplement manufacturers, four points matter more than the headline CFU claim: the exact strains, what the CFU number represents, what supports the shelf life and what the quotation actually includes.
Which Part of the Probiotic Supply Chain Do You Need?
The term “probiotic manufacturer” can refer to companies with very different roles.
| Partner Role | What It Handles |
|---|---|
| Strain developer | Develops or owns probiotic strains and provides supporting technical or research files |
| Culture supplier | Supplies bulk probiotic cultures, specifications and storage instructions |
| Finished-dose manufacturer | Handles formulation, filling, packaging and finished-batch release |
| Private label program | Provides stock or semi-custom products through a finished-dose manufacturer |
Some probiotic companies manage fermentation, freeze-drying and finished production within one organization. Others focus on finished-dose manufacturing and source cultures from specialist suppliers.
Both models can work. The important point is knowing which part of the project each supplier is quoting.
A brand looking for an exclusive, clinically studied strain may need to work with the strain owner and the finished-product factory. A brand launching a conventional private label capsule may only need a manufacturer with established ingredient sourcing, appropriate production controls and a relevant finished-product history.
The initial request should make the expected level of support clear:
- Ready-to-label stock formula
- Modified stock formula
- Fully custom blend
- Specific branded strain
- Finished production using brand-nominated ingredients
Without this distinction, quotations may appear comparable even though they include very different development work.
Four Details That Can Change a Probiotic Quote
1. The Exact Strains
“Lactobacillus blend” does not fully identify a probiotic formula.
Probiotic cultures are generally identified by genus, species and strain designation. The NIH probiotic fact sheet for health professionals explains that the strain designation is part of the microorganism’s complete identity.
Two cultures from the same species may come from different suppliers and have different strain references, technical files, storage requirements and commercial positioning.
The project file should identify:
- Full strain designation
- Culture supplier
- Raw material potency
- Storage conditions
- Lot traceability
- Supporting documents required for the destination market
For a multi-strain product, the approved formula should also record the intended input of each strain, even when routine finished-product testing reports only a combined viable count.
A total CFU result can support the overall potency specification, but it may not show how the total is distributed among the individual strains. This is one reason the formula record and raw material traceability remain important.
Strain substitution also needs a clear approval process.
If a selected culture becomes unavailable, replacing it with another strain may affect the product label, stability assumptions, technical positioning and market review. A named strain should not be replaced as though it were an interchangeable inactive ingredient.
The quotation should therefore indicate whether the proposed formula uses:
- Generic cultures selected by the manufacturer
- Named strains selected by the brand
- Proprietary or branded strains
- A supplier-recommended blend that may depend on availability
These options can produce very different prices, even when the total CFU claim looks identical.
2. What the CFU Number Represents
“50 billion CFU” sounds precise, but the number still needs a time point.
In a probiotic project, three CFU figures may be discussed:
Input CFU
The calculated amount added during manufacturing.
Release CFU
The viable count expected or measured when the finished batch is released.
End-of-shelf-life CFU
The minimum viable count targeted through the stated shelf life.
Each figure can lead to a different formula and price.
For example, one supplier may calculate a 30-billion-CFU product from the amount added during blending. Another may add more culture to account for an expected decline during storage and set a finished-product release specification above the label claim.
The second quotation may also include CFU testing and a more protective package. The bottle price will probably be higher, but the two proposals are not based on the same product specification.
The quotation should state:
- CFU per serving
- Whether the figure applies at input, release or through shelf life
- Proposed shelf life
- Finished-product release specification
- Whether an overage is included
- How the overage was calculated
- Planned CFU testing
ISAPP’s guidance on decoding probiotic product labels emphasizes the importance of declaring the minimum viable count through the end of shelf life rather than relying only on the manufacturing-stage amount.
An overage can help account for expected potency loss, but it does not establish shelf life by itself. The calculation still depends on the selected strains, formula, dosage form, packaging and storage conditions.
More overage is not automatically better. Adding additional culture increases cost and may not solve a weak packaging or stability plan.
3. What the Stability Evidence Covers
When a supplier says stability data are available, the next question is what product was actually tested.
The evidence may relate to:
- The raw probiotic culture
- A similar finished formula
- An earlier product using the same strains
- The final formula in its intended retail package
These are different levels of evidence.
Raw culture data help evaluate the ingredient under the supplier’s specified storage conditions. Finished-product stability should reflect the actual culture blend, excipients, dosage form, retail packaging and intended storage environment.
For probiotics, packaging is part of the formulation decision.
Moisture, oxygen, temperature and repeated opening can all affect product performance. A capsule bottle, powder jar and sealed stick pack do not create the same storage conditions.
Before using a stability report to support the proposed shelf life, check whether it matches:
- The selected strains
- The formula
- The dosage form
- The package
- The storage conditions
- The intended shelf life
A stock capsule with an established formula and packaging history does not require the same development work as a new multi-strain gummy.
For a newly developed formula, complete real-time stability results may not be available at the first commercial production. In that situation, the shelf-life basis should identify the related formulation data, packaging assumptions and planned real-time monitoring.
A generic 18- or 24-month the related formulation data, packaging assumptions and planned real-time monitoring.
A generic statement is not enough without that context.
4. Whether the Dosage Form and Packaging Work Together
Experience producing standard gummies does not automatically demonstrate experience with probiotic gummies.
The same principle applies to capsules, powders, tablets and stick packs.
| Product Format | Main Point to Review |
|---|---|
| Capsules | Powder flow, fill consistency, moisture exposure and bottle protection |
| Powder jars | Blend uniformity and moisture entering after repeated opening |
| Stick packs | Film barrier, seal quality and accurate dose distribution |
| Chewable tablets | Compression pressure, moisture and taste |
| Gummies | Heat exposure, water activity and shelf-life viability |
Capsules and dry powders are often practical starting formats, but their stability still depends on the excipients, capsule shell, bottle, seal, desiccant and storage conditions.
Brands considering dry-format production can review Jiabei Health’s capsule supplement manufacturing capabilities for OEM and private label projects.
Stick packs may reduce repeated exposure after opening, but film selection and seal integrity become critical.
Gummies require a different feasibility review. Standard gummy production commonly involves heat and moisture, so the selected culture, addition stage, process conditions and finished package must be considered together.
Jiabei Health’s probiotic gummy manufacturing page outlines the available project direction for brands evaluating this dosage form.
The format should be chosen before the formula and packaging are finalized. Starting with a label design and trying to fit the manufacturing process around it usually creates avoidable revisions.
A COA Does Not Answer Every Quality Question
“COA available” sounds reassuring, but it does not identify what was tested.
A probiotic project usually involves three separate layers of evidence.
Raw Material COA
The raw material COA applies to the incoming probiotic culture. It may include identity, potency and microbiological results for that ingredient lot.
Finished-Product COA
The finished-product COA applies to the manufactured batch. Depending on the approved specification, it may include CFU, microbiological limits, heavy metals, appearance and unit-weight results.
Stability Records
Stability records show how the finished product changes over time under defined storage conditions. They connect the formula, package, testing interval and shelf-life claim.
Each document answers a different question.
The raw material report covers the ingredient entering production. The finished-product COA covers the released batch. End-of-shelf-life potency requires evidence beyond the initial batch-release result.
When testing is included in a quotation, the scope should clarify whether it covers:
- Raw material document review
- Finished-product CFU testing
- Microbiological and contaminant testing
- Retained-sample or stability monitoring
For multi-strain products, the test method should also be understood. A combined viable count may support the overall CFU specification without separately quantifying every strain.
How to Compare Probiotic Supplement Manufacturers on the Same Basis
Compare the scope before comparing the bottle price.
| Quote Item | What to Compare |
|---|---|
| Strains | Generic, named or proprietary strains |
| Potency | Input, release or end-of-shelf-life CFU |
| Overage | Included, excluded or still to be calculated |
| Testing | Raw material review or finished-product testing |
| Packaging | Standard package or additional moisture protection |
| Stability | Existing evidence or further work required |
A noticeably lower quotation may exclude potency overage, finished-product CFU testing, desiccants, higher-barrier packaging or stability work.
That may still be a workable offer. It is simply a different scope.
Before selecting a supplier, confirm five points:
- Which strains are included?
- What does the quoted CFU represent?
- What packaging is included?
- Which tests are included in the price?
- What supports the proposed shelf life?
Once these details match, the commercial comparison becomes much clearer.
Preparing a probiotic RFQ?
Include the strain list, CFU basis, dosage form, shelf-life target, packaging and order quantity. These details allow the manufacturer to review feasibility before quoting a bottle price.
What Must Be Locked Before Probiotic Production
Before production begins, the project file should contain:
- Final strain list and suppliers
- Approved formula and serving size
- Defined CFU claim
- Finished-product release specification
- Testing scope
- Packaging specification
- Shelf-life basis
- Written change-control requirements
The destination market should also be confirmed before the formula is locked. Otherwise, a strain, claim or label may need to be changed after sampling.
For products offered in the United States, manufacturing should follow the applicable dietary supplement cGMP requirements. The FDA’s dietary supplement cGMP guidance explains the requirements for manufacturing, packaging, labeling and holding dietary supplements.
FDA registration should not be described as FDA approval of an individual product.
MOQ and lead time should be stated separately for manufacturing, cultures and packaging. A standard production timeline may begin only after the formula, ingredients, artwork and packaging have been approved.
Can Jiabei Health Support the Project?
Jiabei Health handles finished-dose and private label production rather than claiming that every probiotic strain is developed in-house.
We can review capsule, powder and gummy projects based on the selected strains, target CFU, dosage form, packaging, shelf life and destination market. Gummy projects require a separate feasibility assessment because their processing and moisture conditions differ from dry formats.
For a technical review and quotation, send the available formula direction, order quantity and market requirements through the Jiabei Health contact page.
Frequently Asked Questions
What does end-of-shelf-life CFU mean?
It is the minimum viable count targeted through the stated shelf life, rather than only the amount added during manufacturing.
The claim should be supported by relevant formulation data, packaging and defined storage conditions.
What information is needed for a probiotic manufacturing quote?
Provide the target market, dosage form, preferred strains, target CFU, CFU time point, shelf-life expectation, packaging, testing requirements and order quantity.
Without these details, two manufacturers may prepare prices for substantially different products.
Final Thought
A useful quotation should tell you which strains are being used, what the CFU claim means, what supports the shelf life and what the price includes.
Without those details, the bottle price is only a partial number.
